The in vivo importance of loss of sensitivity to TRAIL-mediated apoptosis has been demonstrated by clinical studies that have shown a correlation between low TRAIL receptor expression, poor prognosis, and tumor recurrence45. This evidence concerns the gene TNFSF10 and neoplasm.